FDA.reportPublic FDA data

NEVIRAPINE

Substance profile for UNII 99DK7FVK1H, enriched with FDA NDC listings, DailyMed labels, legacy aliases, and open chemistry identifiers.

Chemical structure for NEVIRAPINE
Structure render from PubChem CID 4463

Substance Identity#

UNII
99DK7FVK1H
Preferred term
NEVIRAPINE
Registry number
129618-40-2
Ingredient type
INGREDIENT SUBSTANCE
Molecular formula
C15H14N4O
Chemical structure for NEVIRAPINE
Structure render from PubChem CID 4463

Chemical And Database Identifiers#

InChIKey
NQDJXKOVJZTUJA-UHFFFAOYSA-N
SMILES
CC1=C2NC(=O)C3=CC=CN=C3N(C4CC4)C2=NC=C1
RxCUI
53654
PubChem
4463
NCIt
C29277
INN ID
6815

Open Chemistry Sources#

Source, Identifier, Link table
SourceIdentifierLink
PubChem Compound4463https://pubchem.ncbi.nlm.nih.gov/compound/4463
PubChem InChIKey SearchNQDJXKOVJZTUJA-UHFFFAOYSA-Nhttps://pubchem.ncbi.nlm.nih.gov/#query=NQDJXKOVJZTUJA-UHFFFAOYSA-N
RxNorm53654https://mor.nlm.nih.gov/RxNav/search?searchBy=RXCUI&searchTerm=53654
NCI ThesaurusC29277https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C29277
FDA Substance Registration System99DK7FVK1Hhttps://precision.fda.gov/uniisearch/srs/unii/99DK7FVK1H

DailyMed Socrata Ingredients#

Ingredient, Type, UNII table
IngredientTypeUNIIDailyMed labelSPL versionUploaded
NEVIRAPINEACTIVE MOIETY99DK7FVK1HThese highlights do not include all the information needed to use nevirapine tablets, USP safely and effectively. See full prescribing information for nevirapine tablets, USP. Nevirapine tablets, USP 200 mg, for oral use Initial U.S. Approval: 19961
NEVIRAPINEACTIVE INGREDIENT99DK7FVK1HThese highlights do not include all the information needed to use nevirapine tablets, USP safely and effectively. See full prescribing information for nevirapine tablets, USP. Nevirapine tablets, USP 200 mg, for oral use Initial U.S. Approval: 19961
NEVIRAPINEACTIVE INGREDIENT99DK7FVK1HThese highlights do not include all the information needed to use nevirapine tablets safely and effectively. See full prescribing information for nevirapine tablets. Nevirapine Tablets USP, 200 mg Initial U.S. Approval: 19961
NEVIRAPINEACTIVE MOIETY99DK7FVK1HThese highlights do not include all the information needed to use nevirapine tablets safely and effectively. See full prescribing information for nevirapine tablets. Nevirapine Tablets USP, 200 mg Initial U.S. Approval: 19961
NEVIRAPINEACTIVE INGREDIENT99DK7FVK1HThese highlights do not include all the information needed to use VIRAMUNE XR safely and effectively. See full prescribing information for VIRAMUNE XR. Viramune XR® (nevirapine) Extended-Release Tablets, for oral use Initial U.S. Approval: 19961
NEVIRAPINEACTIVE MOIETY99DK7FVK1HThese highlights do not include all the information needed to use VIRAMUNE XR safely and effectively. See full prescribing information for VIRAMUNE XR. Viramune XR® (nevirapine) Extended-Release Tablets, for oral use Initial U.S. Approval: 19961
NEVIRAPINEACTIVE INGREDIENT99DK7FVK1HThese highlights do not include all the information needed to use VIRAMUNE safely and effectively. See full prescribing information for VIRAMUNE. Viramune® (nevirapine) tablets 200 mg Viramune® (nevirapine) oral suspension 50 mg/5 mL Initial U.S. Approval: 19961
nevirapineACTIVE MOIETY99DK7FVK1HThese highlights do not include all the information needed to use VIRAMUNE safely and effectively. See full prescribing information for VIRAMUNE. Viramune® (nevirapine) tablets 200 mg Viramune® (nevirapine) oral suspension 50 mg/5 mL Initial U.S. Approval: 19961
NEVIRAPINEACTIVE MOIETY99DK7FVK1HNEVIRAPINE TABLET, EXTENDED RELEASE [SANDOZ INC]13
NEVIRAPINEACTIVE INGREDIENT99DK7FVK1HNEVIRAPINE TABLET, EXTENDED RELEASE [SANDOZ INC]13
NEVIRAPINEACTIVE INGREDIENT99DK7FVK1HVIRAMUNE (NEVIRAPINE) SUSPENSION VIRAMUNE (NEVIRAPINE) TABLET [BOEHRINGER INGELHEIM PHARMACEUTICALS INC.]13
NEVIRAPINEACTIVE MOIETY99DK7FVK1HVIRAMUNE (NEVIRAPINE) SUSPENSION VIRAMUNE (NEVIRAPINE) TABLET [BOEHRINGER INGELHEIM PHARMACEUTICALS INC.]13
NEVIRAPINEACTIVE INGREDIENT99DK7FVK1HVIRAMUNE (NEVIRAPINE) TABLET, EXTENDED RELEASE [BOEHRINGER INGELHEIM PHARMACEUTICALS, INC.]9
NEVIRAPINEACTIVE MOIETY99DK7FVK1HVIRAMUNE (NEVIRAPINE) TABLET, EXTENDED RELEASE [BOEHRINGER INGELHEIM PHARMACEUTICALS, INC.]9
NEVIRAPINEACTIVE INGREDIENT99DK7FVK1HNEVIRAPINE TABLET [CAMBER PHARMACEUTICALS, INC.]8
NEVIRAPINEACTIVE MOIETY99DK7FVK1HNEVIRAPINE TABLET [CAMBER PHARMACEUTICALS, INC.]8
NEVIRAPINEACTIVE INGREDIENT99DK7FVK1HNEVIRAPINE EXTENDED RELEASE (NEVIRAPINE) TABLET [ALVOGEN INC. ]7
NEVIRAPINEACTIVE MOIETY99DK7FVK1HNEVIRAPINE EXTENDED RELEASE (NEVIRAPINE) TABLET [ALVOGEN INC. ]7
NEVIRAPINEACTIVE INGREDIENT99DK7FVK1HNEVIRAPINE TABLET [BRECKENRIDGE PHARMACEUTICAL, INC.]6
NEVIRAPINEACTIVE MOIETY99DK7FVK1HNEVIRAPINE TABLET [BRECKENRIDGE PHARMACEUTICAL, INC.]6
NEVIRAPINEACTIVE INGREDIENT99DK7FVK1HNEVIRAPINE TABLET [ALVOGEN INC. ]5
NEVIRAPINEACTIVE MOIETY99DK7FVK1HNEVIRAPINE TABLET [ALVOGEN INC. ]5
NEVIRAPINEACTIVE MOIETY99DK7FVK1HNEVIRAPINE SUSPENSION [AUROBINDO PHARMA LIMITED]4
NEVIRAPINEACTIVE INGREDIENT99DK7FVK1HNEVIRAPINE TABLET [AMNEAL PHARMACEUTICALS OF NEW YORK, LLC]4
NEVIRAPINEACTIVE MOIETY99DK7FVK1HNEVIRAPINE TABLET [AMNEAL PHARMACEUTICALS OF NEW YORK, LLC]4
NEVIRAPINEACTIVE INGREDIENT99DK7FVK1HNEVIRAPINE TABLET [APOTEX CORP]4
NEVIRAPINEACTIVE MOIETY99DK7FVK1HNEVIRAPINE TABLET [APOTEX CORP]4
NEVIRAPINEACTIVE INGREDIENT99DK7FVK1HNEVIRAPINE TABLET [AUROBINDO PHARMA LIMITED]4
NEVIRAPINEACTIVE MOIETY99DK7FVK1HNEVIRAPINE TABLET [AUROBINDO PHARMA LIMITED]4
NEVIRAPINEACTIVE MOIETY99DK7FVK1HNEVIRAPINE TABLET [MYLAN PHARMACEUTICALS INC.]4
NEVIRAPINEACTIVE INGREDIENT99DK7FVK1HNEVIRAPINE TABLET [MYLAN PHARMACEUTICALS INC.]4
NEVIRAPINEACTIVE INGREDIENT99DK7FVK1HNEVIRAPINE TABLET [GOLDEN STATE MEDICAL SUPPLY, INC.]3
nevirapineACTIVE MOIETY99DK7FVK1HNEVIRAPINE TABLET [GOLDEN STATE MEDICAL SUPPLY, INC.]3
NEVIRAPINEACTIVE MOIETY99DK7FVK1HNEVIRAPINE TABLET, EXTENDED RELEASE [MYLAN PHARMACEUTICALS INC.]3
NEVIRAPINEACTIVE INGREDIENT99DK7FVK1HNEVIRAPINE TABLET, EXTENDED RELEASE [MYLAN PHARMACEUTICALS INC.]3
NEVIRAPINEACTIVE MOIETY99DK7FVK1HNEVIRAPINE SUSPENSION NEVIRAPINE TABLET [ROXANE LABORATORIES, INC.]2
NEVIRAPINEACTIVE INGREDIENT99DK7FVK1HNEVIRAPINE SUSPENSION NEVIRAPINE TABLET [ROXANE LABORATORIES, INC.]2
NEVIRAPINEACTIVE INGREDIENT99DK7FVK1HNEVIRAPINE TABLET [CIPLA LIMITED]2
NEVIRAPINEACTIVE MOIETY99DK7FVK1HNEVIRAPINE TABLET [CIPLA LIMITED]2
NEVIRAPINEACTIVE MOIETY99DK7FVK1HNEVIRAPINE TABLET, EXTENDED RELEASE [APOTEX CORP]2
NEVIRAPINEACTIVE INGREDIENT99DK7FVK1HNEVIRAPINE TABLET, EXTENDED RELEASE [APOTEX CORP]2
NEVIRAPINEACTIVE INGREDIENT99DK7FVK1HNEVIRAPINE TABLET [AMNEAL-AGILA, LLC]1
NEVIRAPINEACTIVE MOIETY99DK7FVK1HNEVIRAPINE TABLET [AMNEAL-AGILA, LLC]1
NEVIRAPINEACTIVE INGREDIENT99DK7FVK1HNEVIRAPINE TABLET, EXTENDED RELEASE [MYLAN PHARMACEUTICALS INC.]1
NEVIRAPINEACTIVE MOIETY99DK7FVK1HNEVIRAPINE TABLET, EXTENDED RELEASE [MYLAN PHARMACEUTICALS INC.]1